Insider Selling: Whitehawk Therapeutics (NASDAQ:WHWK) Insider Sells 92,460 Shares of Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) insider Bryan Ball sold 92,460 shares of the business’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $3.64, for a total value of $336,554.40. Following the transaction, the insider owned 397,106 shares in the company, valued at approximately $1,445,465.84. This represents a 18.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Bryan Ball also recently made the following trade(s):

• On Monday, April 13th, Bryan Ball sold 26,389 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.46, for a total value of $91,305.94.
• On Friday, April 10th, Bryan Ball sold 6,596 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.43, for a total value of $22,624.28.
• On Thursday, April 9th, Bryan Ball sold 50,000 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.57, for a total value of $178,500.00.
• On Monday, March 2nd, Bryan Ball sold 1,834 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.31, for a total value of $6,070.54.

Whitehawk Therapeutics Price Performance

WHWK traded down $0.10 during trading hours on Wednesday, reaching $3.90. The company’s stock had a trading volume of 316,487 shares, compared to its average volume of 187,321. Whitehawk Therapeutics, Inc. has a fifty-two week low of $1.39 and a fifty-two week high of $4.48. The stock has a market cap of $184.08 million, a PE ratio of 8.30 and a beta of 0.57. The business’s 50-day moving average is $3.40 and its 200-day moving average is $2.76.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.21.

Analysts Set New Price Targets

WHWK has been the topic of a number of recent analyst reports. JonesTrading initiated coverage on Whitehawk Therapeutics in a report on Monday, December 22nd. They issued a “buy” rating and a $7.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Friday, March 27th. Wall Street Zen cut Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Oppenheimer initiated coverage on Whitehawk Therapeutics in a report on Thursday, February 5th. They issued an “outperform” rating and a $6.00 price objective on the stock. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $6.50.

Institutional Trading of Whitehawk Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Orbimed Advisors LLC purchased a new stake in Whitehawk Therapeutics in the third quarter valued at approximately $7,915,000. Suvretta Capital Management LLC purchased a new stake in Whitehawk Therapeutics in the third quarter valued at approximately $7,030,000. Acuta Capital Partners LLC purchased a new stake in Whitehawk Therapeutics in the third quarter valued at approximately $6,480,000. Avoro Capital Advisors LLC purchased a new stake in Whitehawk Therapeutics in the third quarter valued at approximately $5,414,000. Finally, KVP Capital Advisors LP purchased a new stake in Whitehawk Therapeutics in the fourth quarter valued at approximately $5,242,000. Hedge funds and other institutional investors own 52.08% of the company’s stock.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.